<DOC>
	<DOCNO>NCT01541007</DOCNO>
	<brief_summary>Cabazitaxel show significant efficacy second line chemotherapy Docetaxel men metastatic castration resistant prostate cancer . This demonstrate Tropic Study Cabazitaxel show survival superiority compare mitoxantrone . Almost one 4 patient treat Cabazitaxel study require dose reduction dose delay stop treatment due toxicity . ConCab examine another scheduling cabazitaxel see improve tolerability patient receive high percentage treatment plan .</brief_summary>
	<brief_title>A Study Looking Novel Scheduling Cabazitaxel Patients With Metastatic Prostate Cancer</brief_title>
	<detailed_description>ConCab compare standard treatment cabazitaxel 25 mg/m2 every three week experimental schedule 10 mg/m2 5 consecutive week 6 week cycle . In study arm plan cumulative dose cabazitaxel week 18 150 mg/m2 . Our study aim evaluate difference total receive dose relation plan dose measure 2 treatment schedule superior .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Â¨ Histological confirm prostate cancer Macroscopic metastatic disease Prior treatment Docetaxel Castration resistant disease define : Serum testosterone ( &lt; 0.5 ng/ml ) : Increase measurable disease ( RECIST 1.1 , see appendix 10 ) For nonmeasurable disease , appearance least one new lesion nuclear scintigraphy ) A rise PSA previous reference value 2 consecutive occasion least one week apart Written inform consent Less 21 day since prior treatment chemotherapy Less 14 day since radiotherapy surgery start cabazitaxel Less 4 week stop endocrine therapy include antiandrogen , abiraterone new agent . Prior isotope therapy radiotherapy &gt; 30 % bone marrow ( whole pelvic radiotherapy exclusion criterion ) Persistent adverse event previous cancer therapy &gt; grade 1 ( CTCAE Version 4.0 ) exception alopecia . ( With respect peripheral neuropathy nail change grade 2 acceptable ) ECOG performance status &gt; 1 Known CNS malignancy Within 6 month randomization : myocardial infarction , unstable angina , angioplasty , bypass surgery , stroke , TIA , congestive heart failure NYHA class III IV Within 3 month prior randomization : treatment resistant peptic ulcer disease , infectious inflammatory bowel disease , pulmonary embolism Any severe acute chronic medical condition place patient increase risk serious toxicity interfere interpretation study result History hypersensitivity docetaxel polysorbate 80 Inadequate organ bone marrow function evidence : Hemoglobin &lt; 9.0 g/dL Absolute neutrophil count &lt; 1.5 x 109/L , Platelet count &lt; 100 x 109/L , AST/SGOT and/or ALT/SGPT &gt; 1.5 x ULN ; Total bilirubin &gt; 1.0 x ULN , Serum creatinine &gt; 1.5 x ULN . If creatinine 1.0 1.5 x ULN , creatinine clearance calculate accord CKDEPI formula patient creatinine clearance &lt; 60 mL/min exclude ( http : //mdrd.com/ online calculation ) Concurrent plan treatment potent inhibitor inducers cytochrome P450 3A4/5 . A one week wash period necessary patient already treatment . Patients reproductive potential implementing accept effective method contraception .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Castration Resistant</keyword>
</DOC>